Skip to main content
Erschienen in: Japanese Journal of Ophthalmology 6/2018

29.09.2018 | Clinical Investigation

Bevacizumab dosing every 2 weeks for neovascular age-related macular degeneration refractory to monthly dosing

verfasst von: Michael Mimouni, Amit Meshi, Igor Vainer, Assaf Gershoni, Tal Koren, Noa Geffen, Arie Y Nemet, Ori Segal

Erschienen in: Japanese Journal of Ophthalmology | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose:

To evaluate intravitreal bevacizumab every 2 weeks (biweekly) in refractory neovascular age-related macular degeneration (nAMD).

Study design:

Retrospective study.

Methods:

A retrospective study of consecutive nAMD patients unresponsive to monthly intravitreal anti-vascular endothelial growth factor (VEGF) switched to 3–4 biweekly injections.

Results:

Twenty-seven eyes of patients aged 82.08  ± 6.85 years were included. Prior to the 2-week interval bevacizumab injections, 74.1% (n=20) were treated with both bevacizumab and ranibizumab, 11.1% (3 eyes) also received aflibercept and 14.8% (4 eyes) had received prior treatment of monthly bevacizumab (average number of injections 21.5 ± 6.7). Best corrected visual acuity (BCVA) remained stable between baseline (logMAR 0.72± 0.60) and follow-up (0.76± 0.66) (p=0.41). Mean central macular thickness and macular volume did not change significantly between baseline and follow-up (p=0.35 and p=0.60, respectively). Six eyes (22.2%) showed morphologic anatomic improvements, while 19 eyes (70.4%) were stable and two eyes (7.4%) deteriorated from baseline. Subretinal fluid completely resolved in 3 of the eyes and improved in the other 3 eyes and in this group (22.2%) both central macular thickness (326.2 ± 101.4 versus 297.5 ± 97.2, p=0.002) and macular volume (8.69 ± 1.69 versus 8.22 ± 1.43, p=0.03) were significantly reduced. No adverse events were observed in any of the treated eyes.

Conclusion:

This study demonstrates that biweekly bevacizumab injections are effective in nearly one-quarter of nAMD non-responders with no adverse events reported. Switching earlier, rather than later, to this low cost modality may be of benefit for a portion of non-responders to conventional treatment.
Literatur
1.
Zurück zum Zitat Klein R, Klein BE, Jensen SC, Meuer SM. The five-year incidence and progression of age-related maculopathy: the beaver dam eye study. Ophthalmology. 1997;104:7–21.CrossRef Klein R, Klein BE, Jensen SC, Meuer SM. The five-year incidence and progression of age-related maculopathy: the beaver dam eye study. Ophthalmology. 1997;104:7–21.CrossRef
2.
Zurück zum Zitat Klein R, Cruickshanks KJ, Nash SD, Krantz EM, Nieto FJ, Huang GH, et al. The prevalence of age-related macular degeneration and associated risk factors. Arch Ophthalmol. 2010;128:750–8.CrossRef Klein R, Cruickshanks KJ, Nash SD, Krantz EM, Nieto FJ, Huang GH, et al. The prevalence of age-related macular degeneration and associated risk factors. Arch Ophthalmol. 2010;128:750–8.CrossRef
3.
Zurück zum Zitat Tufail A, Patel PJ, Egan C, Hykin P, da Cruz L, Gregor Z, et al. ABC Trial Investigators. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ. 2010;340:c2459.CrossRef Tufail A, Patel PJ, Egan C, Hykin P, da Cruz L, Gregor Z, et al. ABC Trial Investigators. Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. BMJ. 2010;340:c2459.CrossRef
4.
Zurück zum Zitat Klein R, Klein BE, Jensen SC, Mares-Perlman JA, Cruickshanks KJ, Palta M. Age-related maculopathy in a multiracial United States population: the national health and nutrition examination survey III. Ophthalmology. 1999;106:1056–65.CrossRef Klein R, Klein BE, Jensen SC, Mares-Perlman JA, Cruickshanks KJ, Palta M. Age-related maculopathy in a multiracial United States population: the national health and nutrition examination survey III. Ophthalmology. 1999;106:1056–65.CrossRef
5.
Zurück zum Zitat Bird AC. Therapeutic targets in age-related macular disease. J Clin Invest. 2010;120:3033–41.CrossRef Bird AC. Therapeutic targets in age-related macular disease. J Clin Invest. 2010;120:3033–41.CrossRef
6.
Zurück zum Zitat Kaiser PK, Brown DM, Zhang K, Hudson HL, Holz FG, Shapiro H, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol. 2007;144:850–7.CrossRef Kaiser PK, Brown DM, Zhang K, Hudson HL, Holz FG, Shapiro H, et al. Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol. 2007;144:850–7.CrossRef
7.
Zurück zum Zitat Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR. MARINA study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007;114:246–52.CrossRef Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR. MARINA study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology. 2007;114:246–52.CrossRef
8.
Zurück zum Zitat Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. ANCHOR study group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432–44.CrossRef Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. ANCHOR study group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432–44.CrossRef
9.
Zurück zum Zitat Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–31.CrossRef Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–31.CrossRef
10.
Zurück zum Zitat Comparison of Age-related Macular Degeneration Treatments Trials Research G, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: 2-year results. Ophthalmology. 2012;119:1388–98.CrossRef Comparison of Age-related Macular Degeneration Treatments Trials Research G, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: 2-year results. Ophthalmology. 2012;119:1388–98.CrossRef
11.
Zurück zum Zitat Investigators IS, Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119:1399–411.CrossRef Investigators IS, Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119:1399–411.CrossRef
12.
Zurück zum Zitat Falkenstein IA, Cheng L, Morrison VL, Kozak I, Tammewar AM, Freeman WR. Standardized visual acuity results associated with primary versus secondary bevacizumab (avastin) treatment for choroidal neovascularization in age-related macular degeneration. Retina. 2007;27:701–6.CrossRef Falkenstein IA, Cheng L, Morrison VL, Kozak I, Tammewar AM, Freeman WR. Standardized visual acuity results associated with primary versus secondary bevacizumab (avastin) treatment for choroidal neovascularization in age-related macular degeneration. Retina. 2007;27:701–6.CrossRef
13.
Zurück zum Zitat Emerson MV, Lauer AK, Flaxel CJ, Wilson DJ, Francis PJ, Stout JT, et al. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina. 2007;27:439–44.CrossRef Emerson MV, Lauer AK, Flaxel CJ, Wilson DJ, Francis PJ, Stout JT, et al. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina. 2007;27:439–44.CrossRef
14.
Zurück zum Zitat El-Mollayess GM, Mahfoud Z, Schakal AR, Salti HI, Jaafar D, Bashshur ZF. Fixed-interval versus OCT-guided variable dosing of intravitreal bevacizumab in the management of neovascular age-related macular degeneration: a 12-month randomized prospective study. Am J Ophthalmol. 2012;153(481–9):e1. El-Mollayess GM, Mahfoud Z, Schakal AR, Salti HI, Jaafar D, Bashshur ZF. Fixed-interval versus OCT-guided variable dosing of intravitreal bevacizumab in the management of neovascular age-related macular degeneration: a 12-month randomized prospective study. Am J Ophthalmol. 2012;153(481–9):e1.
15.
Zurück zum Zitat Solomon SD, Lindsley KB, Krzystolik MG, Vedula SS, Hawkins BS. Intravitreal bevacizumab versus ranibizumab for treatment of neovascular age-related macular degeneration: findings from a cochrane systematic review. Ophthalmology. 2016;123(70–7):e1. Solomon SD, Lindsley KB, Krzystolik MG, Vedula SS, Hawkins BS. Intravitreal bevacizumab versus ranibizumab for treatment of neovascular age-related macular degeneration: findings from a cochrane systematic review. Ophthalmology. 2016;123(70–7):e1.
16.
Zurück zum Zitat Lazzeri S, Ripandelli G, Sartini MS, Parravano M, Varano M, Nardi M, et al. Aflibercept administration in neovascular age-related macular degeneration refractory to previous anti-vascular endothelial growth factor drugs: a critical review and new possible approaches to move forward. Angiogenesis. 2015;18:397–432.CrossRef Lazzeri S, Ripandelli G, Sartini MS, Parravano M, Varano M, Nardi M, et al. Aflibercept administration in neovascular age-related macular degeneration refractory to previous anti-vascular endothelial growth factor drugs: a critical review and new possible approaches to move forward. Angiogenesis. 2015;18:397–432.CrossRef
17.
Zurück zum Zitat Otsuji T, Nagai Y, Sho K, Tsumura A, Koike N, Tsuda M, et al. Initial non-responders to ranibizumab in the treatment of age-related macular degeneration (AMD). Clin Ophthalmol. 2013;7:1487–90.CrossRef Otsuji T, Nagai Y, Sho K, Tsumura A, Koike N, Tsuda M, et al. Initial non-responders to ranibizumab in the treatment of age-related macular degeneration (AMD). Clin Ophthalmol. 2013;7:1487–90.CrossRef
18.
Zurück zum Zitat Krebs I, Schmetterer L, Boltz A, Told R, Vecsei-Marlovits V, Egger S, et al. MANTA Research Group. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol. 2013;97:266–71.CrossRef Krebs I, Schmetterer L, Boltz A, Told R, Vecsei-Marlovits V, Egger S, et al. MANTA Research Group. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol. 2013;97:266–71.CrossRef
19.
Zurück zum Zitat Suzuki M, Nagai N, Izumi-Nagai K, Shinoda H, Koto T, Uchida A, et al. Predictive factors for non-response to intravitreal ranibizumab treatment in age-related macular degeneration. Br J Ophthalmol. 2014;98:1186–91.CrossRef Suzuki M, Nagai N, Izumi-Nagai K, Shinoda H, Koto T, Uchida A, et al. Predictive factors for non-response to intravitreal ranibizumab treatment in age-related macular degeneration. Br J Ophthalmol. 2014;98:1186–91.CrossRef
20.
Zurück zum Zitat Lanzetta P, Mitchell P, Wolf S, Veritti D. Different antivascular endothelial growth factor treatments and regimens and their outcomes in neovascular age-related macular degeneration: a literature review. Br J Ophthalmol. 2013;97:1497–507.CrossRef Lanzetta P, Mitchell P, Wolf S, Veritti D. Different antivascular endothelial growth factor treatments and regimens and their outcomes in neovascular age-related macular degeneration: a literature review. Br J Ophthalmol. 2013;97:1497–507.CrossRef
21.
Zurück zum Zitat Segal O, Mimouni M, Nemet AY, Segev F, Geffen N, Nesher R. The effects of the frequency of the initial treatment with intravitreal bevacizumab on macular volume and visual acuity. J Ocul Pharmacol Ther. 2015;31:277–81.CrossRef Segal O, Mimouni M, Nemet AY, Segev F, Geffen N, Nesher R. The effects of the frequency of the initial treatment with intravitreal bevacizumab on macular volume and visual acuity. J Ocul Pharmacol Ther. 2015;31:277–81.CrossRef
22.
Zurück zum Zitat Rosenfeld PJ, Heier JS, Hantsbarger G, Shams N. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology. 2006;113(623):e1. Rosenfeld PJ, Heier JS, Hantsbarger G, Shams N. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology. 2006;113(623):e1.
23.
Zurück zum Zitat Stewart MW, Rosenfeld PJ, Penha FM, Wang F, Yehoshua Z, Bueno-Lopez E, et al. Pharmacokinetic rationale for dosing every 2 versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). Retina. 2012;32:434–57.PubMed Stewart MW, Rosenfeld PJ, Penha FM, Wang F, Yehoshua Z, Bueno-Lopez E, et al. Pharmacokinetic rationale for dosing every 2 versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye). Retina. 2012;32:434–57.PubMed
24.
Zurück zum Zitat Barikian A, Mahfoud Z, Abdulaal M, Safar A, Bashshur ZF. Induction with intravitreal bevacizumab every 2 weeks in the management of neovascular age-related macular degeneration. Am J Ophthalmol. 2015;159:131–7.CrossRef Barikian A, Mahfoud Z, Abdulaal M, Safar A, Bashshur ZF. Induction with intravitreal bevacizumab every 2 weeks in the management of neovascular age-related macular degeneration. Am J Ophthalmol. 2015;159:131–7.CrossRef
25.
Zurück zum Zitat Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. VIEW 1 and VIEW 2 study groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537–48.CrossRef Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, et al. VIEW 1 and VIEW 2 study groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537–48.CrossRef
26.
Zurück zum Zitat Witkin AJ, Rayess N, Garg SJ, Maguire JI, Storey P, Kaiser RS, et al. Alternating bi-weekly intravitreal ranibizumab and bevacizumab for refractory neovascular age-related macular degeneration with pigment epithelial detachment. Semin Ophthalmol. 2017;32(3):309–315.CrossRef Witkin AJ, Rayess N, Garg SJ, Maguire JI, Storey P, Kaiser RS, et al. Alternating bi-weekly intravitreal ranibizumab and bevacizumab for refractory neovascular age-related macular degeneration with pigment epithelial detachment. Semin Ophthalmol. 2017;32(3):309–315.CrossRef
27.
Zurück zum Zitat Simader C, Ritter M, Bolz M, Deak GG, Mayr-Sponer U, Golbaz I, et al. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration. Ophthalmology. 2014;121:1237–45.CrossRef Simader C, Ritter M, Bolz M, Deak GG, Mayr-Sponer U, Golbaz I, et al. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration. Ophthalmology. 2014;121:1237–45.CrossRef
28.
Zurück zum Zitat Amoaku WM, Chakravarthy U, Gale R, Gavin M, Ghanchi F, Gibson J, et al. Defining response to anti-VEGF therapies in neovascular AMD. Eye (Lond). 2015;29:721–31.CrossRef Amoaku WM, Chakravarthy U, Gale R, Gavin M, Ghanchi F, Gibson J, et al. Defining response to anti-VEGF therapies in neovascular AMD. Eye (Lond). 2015;29:721–31.CrossRef
29.
Zurück zum Zitat Tozer K, Roller AB, Chong LP, Sadda S, Folk JC, Mahajan VB, et al. Combination therapy for neovascular age-related macular degeneration refractory to anti-vascular endothelial growth factor agents. Ophthalmology. 2013;120:2029–34.CrossRef Tozer K, Roller AB, Chong LP, Sadda S, Folk JC, Mahajan VB, et al. Combination therapy for neovascular age-related macular degeneration refractory to anti-vascular endothelial growth factor agents. Ophthalmology. 2013;120:2029–34.CrossRef
31.
Zurück zum Zitat Curtis LH, Hammill BG, Schulman KA, Cousins SW. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol. 2010;128:1273–9.CrossRef Curtis LH, Hammill BG, Schulman KA, Cousins SW. Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol. 2010;128:1273–9.CrossRef
Metadaten
Titel
Bevacizumab dosing every 2 weeks for neovascular age-related macular degeneration refractory to monthly dosing
verfasst von
Michael Mimouni
Amit Meshi
Igor Vainer
Assaf Gershoni
Tal Koren
Noa Geffen
Arie Y Nemet
Ori Segal
Publikationsdatum
29.09.2018
Verlag
Springer Japan
Erschienen in
Japanese Journal of Ophthalmology / Ausgabe 6/2018
Print ISSN: 0021-5155
Elektronische ISSN: 1613-2246
DOI
https://doi.org/10.1007/s10384-018-0619-0

Weitere Artikel der Ausgabe 6/2018

Japanese Journal of Ophthalmology 6/2018 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Open Access 22.02.2024 | Peeling | Originalien

Selektive Vitalfarbstoffe in der Makulachirurgie

Erhöhen sie die Wahrscheinlichkeit der intraoperativen ILM-Identifizierung auch bei einem erfahrenen Operateur?

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.